STOCK TITAN
  1. Home
  2. News
  3. OLMA

Olema Pharmaceuticals Inc - OLMA STOCK NEWS

Welcome to our dedicated news page for Olema Pharmaceuticals (Ticker: OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Olema Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Olema Pharmaceuticals's position in the market.

News
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
Rhea-AI Summary
Olema Pharmaceuticals, Inc. announces CEO participation in a panel on Breast Cancer at the 2024 CG Horizons in Oncology Virtual Conference. The company focuses on developing targeted therapies for women's cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
conferences
-
News
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Olema Pharmaceuticals, Inc. grants stock options to new employees, allowing them to purchase 60,000 shares of common stock. The options vest over four years and have an exercise price of $10.89 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
none
-
News
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Olema Pharmaceuticals, Inc. reports strong financials with $261.8 million in cash equivalents. Positive clinical results for palazestrant in Q4 2023. Initiates pivotal Phase 3 trial with top-line results expected in 2026. Multiple Phase 2 studies fully enrolled. Corporate update includes progress in KAT6 program and clinical collaborations. Cash, cash equivalents, and marketable securities of $261.8 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.62%
Tags
earnings
News
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
Rhea-AI Summary
Olema Pharmaceuticals, Inc. announces the selection of a data publication in Molecular Cancer Therapeutics highlighting the unique properties of palazestrant (OP-1250) as a potential therapy for advanced ER+/HER2- breast cancer. The pre-clinical results demonstrate its distinct mechanism of action and promising efficacy in reducing tumor growth, especially in ESR1-mutant ER+ breast cancer models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.47%
Tags
none
-
News
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Olema Pharmaceuticals, Inc. granted stock options to a new employee for 50,000 shares of common stock. The options vest over four years, with a 10-year term and an exercise price of $14.80 per share. This grant was made under the 2022 Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.01%
Tags
none
-
News
Olema Oncology to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Olema Pharmaceuticals, Inc. announced their participation in several upcoming investor conferences, including the Oppenheimer 34th Annual Healthcare Life Sciences Conference, TD Cowen’s 44th Annual Health Care Conference, and the Jefferies Biotech on the Bay Summit. The company's President and CEO, Sean P. Bohen, M.D., Ph.D., and COO Shane Kovacs will be participating in various discussions and panels at these events. The webcasts of the events will be available on Olema's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
conferences
News
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Olema Pharmaceuticals, Inc. granted stock options to four new employees to purchase 33,600 shares of common stock, effective February 1, 2024. The options vest over four years, with a 10-year term and an exercise price of $15.25 per share. This move is in accordance with the 2022 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
Rhea-AI Summary
Olema Pharmaceuticals, Inc. (OLMA) announced the selection of a development candidate, OP-3136, for the Company’s program targeting KAT6, an epigenetic target dysregulated in breast cancer and other cancers. The compound has demonstrated potent anti-tumor activity and is set to advance into clinical development by the end of 2024. OP-3136 is an orally bioavailable, potent KAT6A/B-selective inhibitor developed in collaboration with Aurigene Oncology. The company presented promising data at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, showing highly selective and potent activity against KAT6A and KAT6B in ER+ breast cancer cell lines. Olema is initiating non-clinical Investigational New Drug (IND) enabling studies to support a potential IND submission to the FDA for OP-3136 by the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.83%
Tags
none
-
News
Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Olema Pharmaceuticals, Inc. (OLMA) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.11%
Tags
conferences
News
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
Rhea-AI Summary
Olema Pharmaceuticals, Inc. (OLMA) announced positive interim results from a Phase 1b/2 clinical study of palazestrant (OP-1250) in combination with CDK4/6 inhibitors ribociclib and palbociclib. The company also outlined the trial design for the ongoing Phase 3 OPERA-01 monotherapy trial and announced the activation of clinical sites and initiation of patient dosing. Olema will host an investor conference call on December 6, 2023, to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.34%
Tags
clinical trial
Stock OLMA logo
Olema Pharmaceuticals Inc

Nasdaq:OLMA

OLMA Rankings

#2853 Ranked by Market Cap
#22 Ranked by Stock Gains
N/A Ranked by Dividends

OLMA Stock Data

607.23M
28.47M
3.94%
96.27%
14.49%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
San Francisco

About OLMA

olema oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. our lead program, op-1250, a potential best-in-class complete estrogen receptor antagonist (ceran), is in development to treat estrogen receptor-positive (er+), human epidermal growth factor receptor 2-negative (her2-) breast cancer. olema recently initiated a phase 1/2 dose-escalation and expansion clinical trial of op-1250. we are supported in our mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies. for more information about the company please visit www.olema.com.